(13-107) Evaluating the effects on disease activity when switching rheumatology patients from reference self-administered tocilizumab to biosimilar

Wednesday, December 10, 2025

3:15 PM - 4:15 PM

Location: Bayside A, Level 1

Residency Program: Baylor Health Enterprises
Residency Program Type: PGY1 (Community-Based Pharmacy)
Residency Program Location: Texas

Co-Author(s): Da Sol Kim, Tim Reynolds, Jenay Kyles, Sweta Patel

Primary Author(s)